LYEL Stock Analysis: Buy, Sell, or Hold?
LYEL - Lyell Immunopharma, Inc. Common Stock
$13.00
0.37 (2.93%)
▲
5d:
+4.5%
30d:
-25.54%
90d:
-34.01%
BUY
HIGH Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When LYEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LYEL shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: LYEL shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: LYEL is currently trading at $13.00, which is considered slightly low relative to its 30-day fair value range of $12.42 to $16.49.
Technical Outlook: Technically, LYEL is in a strong downtrend. Immediate support is located at $11.66, while resistance sits at $14.14.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.17 (+185.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LYEL is in a strong downtrend. Immediate support is located at $11.66, while resistance sits at $14.14.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.17 (+185.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$12.42 -
$16.49
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 185.9% below Wall St target ($37.17)
Trading Range Analysis
30-Day Trading Range
$12.42 -
$16.49
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$1.13
(8.7%)
Support & Resistance Levels
Support Level
$11.66
Resistance Level
$14.14
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.63
Wall Street Target
$37.17
(+185.9%)
Revenue Growth (YoY)
-71.4%
Share & Embed Analysis
Last updated: June 25, 2026 12:32 AM ET
Data refreshes hourly during market hours. Next update: 1:32 AM
Data refreshes hourly during market hours. Next update: 1:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Lynn Seely
SELL
7455 shares
2026-02-11
Stephen J Hill
SELL
1236 shares
2026-02-11
Gary K Lee
SELL
1671 shares
2026-02-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 58 HOLD |
